1998
Increased Striatal Dopamine Transmission in Schizophrenia: Confirmation in a Second Cohort
Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M. Increased Striatal Dopamine Transmission in Schizophrenia: Confirmation in a Second Cohort. American Journal Of Psychiatry 1998, 155: 761-767. PMID: 9619147, DOI: 10.1176/ajp.155.6.761.Peer-Reviewed Original ResearchConceptsD2 receptor availabilityAcute amphetamine challengeStriatal dopamine transmissionAmphetamine challengeReceptor availabilityDopamine releaseHealthy subjectsDopamine transmissionDopamine D2 receptor availabilityExcess dopamine releaseStriatal dopamine releaseComparison groupD2 receptor radiotracerHistory of alcoholDSM-IV criteriaSingle photon emissionNew cohortUntreated patientsReceptor radiotracerSchizophrenic patientsPatientsSecond cohortParental socioeconomic statusPositive symptomsSubstance abuse
1996
Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796.
Seibyl JP, Zea-Ponce Y, Brenner L, Baldwin RM, Krystal JH, Offord SJ, Mochoviak S, Charney DS, Hoffer PB, Innis RB. Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796. Journal Of Nuclear Medicine 1996, 37: 11-5. PMID: 8543979.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntipsychotic AgentsBenzamidesBrainContrast MediaCorpus StriatumDopamine AntagonistsDose-Response Relationship, DrugFeasibility StudiesHumansInfusions, IntravenousIodine RadioisotopesMalePiperazinesPyrrolidinesReceptors, DopamineReceptors, Dopamine D2Time FactorsTomography, Emission-Computed, Single-PhotonConceptsHealthy male subjectsContinuous infusionBrain activity levelsReceptor occupancyStriatal activityAntipsychotic agentsDopamine receptorsMale subjectsSerial venous blood samplesSide effect ratingsBrain time-activity curvesContinuous intravenous infusionExtrapyramidal side effectsStriatal dopamine receptorsVenous blood samplesDopamine receptor occupancySerial SPECT imagesClinical responseExtrapyramidal symptomsIntravenous infusionSerum prolactinAntipsychotic drugsBlood samplesSide effectsTime-activity curves
1993
Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients
Licinio J, Seibyl JP, Altemus M, Charney DS, Krystal JH. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. American Journal Of Psychiatry 1993, 150: 1408-1410. PMID: 8102512, DOI: 10.1176/ajp.150.9.1408.Peer-Reviewed Original ResearchConceptsNeuroleptic-free schizophrenic patientsInterleukin-2Dopaminergic neurotransmissionSchizophrenic patientsElevated CSF levelsAbnormal brain morphologyInterleukin-1 alphaAutoimmune phenomenaCSF levelsHealthy subjectsBrain morphologyPatientsElevated levelsNeurotransmissionCell growthAutoimmunityLevelsSchizophrenia
1991
NO Association Between an Allele at the D2 Dopamine Receptor Gene (DRD2) and Alcoholism
Gelernter J, O'Malley S, Risch N, Kranzler HR, Krystal J, Merikangas K, Kennedy JL, Kidd KK. NO Association Between an Allele at the D2 Dopamine Receptor Gene (DRD2) and Alcoholism. JAMA 1991, 266: 1801-1807. PMID: 1832467, DOI: 10.1001/jama.1991.03470130081033.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlcoholismAllelesDNAFemaleHumansMaleMiddle AgedReceptors, DopamineReceptors, Dopamine D2ConceptsControl groupA1 allelePopulation control groupPhysical withdrawal symptomsRandom population controlsSignificant differencesAge of onsetRecent alcohol consumptionAllele frequenciesD2 dopamine receptor geneAntisocial personality disorderWithdrawal symptomsFamily historyAlcoholic subjectsDirect structured interviewsGroup overallAllelic associationDopamine receptor geneAlcohol consumptionAlcohol dependenceControl populationPositive allelic associationAlcoholismPersonality disorderWhite individualsMechanisms of action of atypical antipsychotic drugs Implications for novel therapeutic strategies for schizophrenia
Deutch A, Moghaddam B, Innis R, Krystal J, Aghajanian G, Bunney B, Charney D. Mechanisms of action of atypical antipsychotic drugs Implications for novel therapeutic strategies for schizophrenia. Schizophrenia Research 1991, 4: 121-156. PMID: 1674882, DOI: 10.1016/0920-9964(91)90030-u.Peer-Reviewed Original ResearchMeSH KeywordsAntipsychotic AgentsBrainHumansReceptors, DopamineReceptors, SerotoninSchizophreniaSchizophrenic PsychologyConceptsAtypical antipsychotic drugsAntipsychotic drugsDopamine D2 receptor antagonismD2 receptor antagonismAtypical profileNovel therapeutic strategiesDopamine D2 receptorsMechanism of actionAtypical agentsReceptor antagonismClinical dataD2 receptorsTherapeutic strategiesDrug profileDrugs implicationsMode of actionDrugsAntagonismClozapineRacloprideSerotoninSubtypesSchizophrenia